人类的核受体 由 48 种转录因子组成。其中,10 种被视为孤核受体 (ONR),因为尚未确定天然配体,而 26 种以前是孤儿核受体,但在发现各自的天然配体后,现在被标记为已采用核受体。尽管已采用核受体与内源性配体结合,但核受体功能是否受配体调节仍不清楚。其余 12 种核受体使用内分泌激素作为内源性配体,被归类为内分泌核受体。配体与核受体结合通常会诱导构象变化,使核受体能够与基因组中的靶 DNA 基序(称为核受体反应元件 (NRRE))结合,并募集调节靶基因转录的共调节蛋白。由于核受体可能受配体调节或可用作药物,因此它们是使用小分子化合物的有吸引力的治疗靶点。孤儿核受体为揭示影响人类健康的新型调节系统提供了独特的资源,也为多种人类疾病提供了药物靶点。核受体配体已用于多种重要的治疗领域,例如乳腺癌、皮肤病和糖尿病。
Nuclear receptors consist of 48 transcription factors in humans. Of these, 10 are considered orphan nuclear receptors (ONRs) because the natural ligand has not yet been identified, while 26 are former orphans but are now labeled as adopted NRs after the discovery of their respective natural ligands. Although adopted NRs bind endogenous ligands, it remains unclear whether the NR function is ligand-regulated. The remaining 12 NRs employ endocrine hormones as endogenous ligands and are classified as endocrine NRs. Ligand binding to NRs typically induce a conformational change that enable binding of NRs to target DNA motifs across the genome called nuclear receptor response elements (NRREs) and recruitment of co-regulator proteins that modulate transcription of target genes. Because ONRs could potentially be ligand-regulated or druggable, they are attractive therapeutic targets using small molecule compounds. Orphan nuclear receptors provide a unique resource for uncovering novel regulatory systems that impact human health and also provide drug targets for a variety of human diseases. Ligands of nuclear receptors have been used in several important therapeutic areas, such as breast cancers, skin disorders and diabetes[1][2].
7-[4-(2-Piperidinyl)ethoxy]benzoyl Raloxifene 是一种 LRH-1 受体拮抗剂,其 IC50 值为 3.1 μM。
BI-6015 是一种肝细胞核因子 4α (HNF4α) 拮抗剂,可抑制已知 HNF4α 靶基因的表达,并通过 HNF4α 拮抗作用抑制胰岛素启动子活性,可用于癌症和糖尿病的研究。
BI-6015 (Standard) 是 BI-6015 (MS-V71599) 的分析标准品,可用于研究及分析应用;BI-6015 是一种肝细胞核因子 4α (HNF4α) 拮抗剂,可抑制已知 HNF4α 靶基因的表达,并通过 HNF4α 拮抗作用抑制胰岛素启动子活性,因此可用于癌症和糖尿病的研究。
LRH-1 antagonist-1(Compound 3d2)是一种 Kd 为 1.8 μM 的 LRH-1 拮抗剂,可抑制 LRH-1 转录活性并降低 G0S2 表达,抑制 LRH-1 阳性癌细胞增殖,可用于胰腺癌、结肠癌和乳腺癌研究。
LRH-1 antagonist-1 (Compound 3d2) dihydrochloride 是一种 Kd 为 1.8 μM 的 LRH-1 拮抗剂,可抑制 LRH-1 转录活性并降低 G0S2 表达,抑制 LRH-1 阳性癌细胞增殖,可用于研究胰腺癌、结肠癌和乳腺癌。
NR2F1 agonist 1 是一种可特异性激活恶性细胞休眠程序的核受体 NR2F1 激动剂,其通过上调 NR2F1 及调节休眠的下游靶基因,经 NR2F1 激活在头颈部鳞状细胞癌 (HNSCC) 中诱导神经嵴样生长抑制,并在小鼠原发肿瘤模型中抑制肿瘤生长。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号